OTLC — Oncotelic Therapeutics, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 908259 ·
Last close
$0.02
Market Cap
$11.03M
52W High
$0.11
52W Low
$0.02
ADV30
291,900
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -1,853,385 | -2,193,776 | 393,955,039 | 63,614 | 131,743,498 |
| Dec 2025 | 0 | — | -2,528,560 | 250,348,057 | 393,088,242 | 88,857 | 131,356,683 |
| Sep 2025 | 0 | — | -490,973 | -1,047,365 | 28,156,163 | 409,000 | 20,079,663 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,558,433
Investing CF
—
Financing CF
$1,542,874
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$209,045,388
Inventory
—
Receivables
$2,058
ST Investments
—
EBIT TTM
$359,677,403
Pretax Income TTM
$358,699,903
Interest Exp TTM
$977,500
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$250,000
EBITDA
—
Free Cash Flow
$-54,613
Enterprise Value
$27,026,886
Total Cash
$186,014
Total Debt
$13,894,960
Shares Out
457,512,796
Trailing EPS
$0.59
Book Value
$0.58
ROE
182.6%
ROA
-1.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -3,186,599 | 249,279,832 | 393,088,242 | 131,356,683 | 262,760,595 | -1,383,145 |
| Dec 2024 | 0 | -376,013 | -4,523,932 | 26,677,426 | 19,199,914 | 8,251,631 | -740,277 |
| Dec 2023 | 70,000 | -564,869 | -7,903,093 | 30,014,952 | 18,403,415 | 12,130,129 | -1,321,047 |
| Dec 2022 | 0 | -5,610,574 | 5,094,981 | 36,116,819 | 16,923,407 | 19,409,032 | -1,452,562 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.00
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MTVA | MetaVia Inc. | $11.00M | $1.67 | — |
| SCNX | Scienture Holdings, Inc. | $11.07M | $0.27 | — |
| MBRX | Moleculin Biotech, Inc. | $11.08M | $0.57 | — |
| GDTC | CytoMed Therapeutics Ltd | $10.95M | $0.93 | — |
| CALC | CalciMedica, Inc. | $11.47M | $1.68 | — |
News headlines (Yahoo Finance, 1h cache)
Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th
2026-08-03 12:35 · Yahoo
Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
2026-06-29 12:30 · Yahoo
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
2026-06-17 12:00 · Yahoo
Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote
2026-06-08 12:00 · Yahoo
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies
2026-06-04 12:30 · Yahoo
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
2026-06-02 12:30 · Yahoo
TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics
2026-06-01 11:30 · Yahoo
Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026
2026-05-28 12:30 · Yahoo
Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress
2026-05-15 13:00 · Yahoo
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
2026-05-14 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.